ISSN 1671-5411 CN 11-5329/R
Yan Zhao, Ming Yang, Jianying Cui, Kang Gao, Yiguang Sun, Xiaoqin Sun, Liwei Chen, Jie Ma, Luhua Shen. Feasibility of intravenous administration of aspirin in acute coronary syndrome. J Geriatr Cardiol 2008; 5(4): 212-216.
Citation: Yan Zhao, Ming Yang, Jianying Cui, Kang Gao, Yiguang Sun, Xiaoqin Sun, Liwei Chen, Jie Ma, Luhua Shen. Feasibility of intravenous administration of aspirin in acute coronary syndrome. J Geriatr Cardiol 2008; 5(4): 212-216.

Feasibility of intravenous administration of aspirin in acute coronary syndrome

  • Publish Date: 2008-12-28
  • Objectives To compare the clinical effects of intravenously and orally administered aspirin in the treatment for acute coronary syndrome (ACS), and to evaluate the adverse effects of intravenous administration of aspirin. Methods One hundred and twentyfive patients with unstable angina pectoris or acute myocardial infarction were randomized into three groups: group 1 received intravenous aspirin (300mg/d, n =40), while groups 2 (n =42) and 3 (n =43) received orally administered aspirin (100mg/d and 300mg/d, respectively). The control group included 30 patients with no heart disease or blood disease, and they had never taken aspirin and clopidogrel. Blood samples were taken at 2nd and 7th day of hospitalization. Platelet aggregation and the level of platelet activation marker CD62p were measured and compared among the groups. Patients were followed up for 6 months for the occurrence of major adverse cardiovascular events. Results There were no statistically significant differences in the decrease in adenosine diphosphate (ADP)-induced platelet aggregation rate (12.01± 10.45%, 6.76± 14.62% and 9.73± 16.72%for group 1, group2 and group 3, respectively), the decrease in arachidonic acid (AA)-induced platelet aggregation rate (6.73± 11.34%, 6.95± 12.45% and 7.57 ± 13.11%, respectively), and the decrease in CD62p level (10.89± 18.62%, 8.92± 11.57% and 7.05± 15.67% , respectively). At six months, there were 4 deaths (10%) in group 1, 4 deaths (9.5%) in group 2 and 5 deaths (11.6%) in group 3 (P>0.05). Conclusions Intravenous administration of aspirin provides a new approach as an anti-platelet treatment for ACS patients, especially those who can not tolerate oral administration of aspirin.
  • loading
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2013) PDF downloads(7109) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return